|
|
Volumn 121, Issue 10, 2015, Pages 1529-1530
|
|
Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
INIPARIB;
PERTUZUMAB;
BENZAMIDE DERIVATIVE;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;
ARTICLE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER RESEARCH;
CANCER SURVIVAL;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MALIGNANT NEOPLASTIC DISEASE;
NON SMALL CELL LUNG CANCER;
OVARY CANCER;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
SURVIVAL TIME;
TREATMENT OUTCOME;
TREATMENT PLANNING;
TRIPLE NEGATIVE BREAST CANCER;
ANTAGONISTS AND INHIBITORS;
CLINICAL TRIAL (TOPIC);
FINANCIAL MANAGEMENT;
MOLECULARLY TARGETED THERAPY;
NATIONAL HEALTH ORGANIZATION;
NUMBERS NEEDED TO TREAT;
PATIENT SELECTION;
PERSONALIZED MEDICINE;
STANDARDS;
TRENDS;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
BENZAMIDES;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMANS;
INDIVIDUALIZED MEDICINE;
MOLECULAR TARGETED THERAPY;
NATIONAL CANCER INSTITUTE (U.S.);
NUMBERS NEEDED TO TREAT;
PATIENT SELECTION;
POLY(ADP-RIBOSE) POLYMERASES;
RESEARCH SUPPORT AS TOPIC;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84929009248
PISSN: 0008543X
EISSN: 10970142
Source Type: Journal
DOI: 10.1002/cncr.28994 Document Type: Article |
|
Times cited : (18)
|
|
References (3)
|
